Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173872 | 1.00 | MAPT (0.50) | MAPTALDH1A1HPGDSMN1; SMN2CASP3 | |
| SCHEMBL730909 | 0.88 | ALDH1A1 (0.45) | MAPTALDH1A1HPGDSMN1; SMN2CASP3 | |
| SCHEMBL179168 | 0.85 | ALDH1A1 (0.47) | MAPTALDH1A1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL18561359 | 0.84 | ADORA2A (0.47) | MAPTALDH1A1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL29960281 | 0.83 | HCAR3 (0.50) | ALDH1A1HPGDKDM4EHSD17B10TSHR | |
| SCHEMBL121802 | 0.83 | SLC2A1 (0.41) | MAPTALDH1A1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL20604896 | 0.82 | MAPT (0.44) | MAPTALDH1A1HPGDSMN1; SMN2CASP3 | |
| SCHEMBL30987624 | 0.82 | MAPT (0.44) | MAPTALDH1A1HPGDSMN1; SMN2CASP3 | |
| SCHEMBL20594787 | 0.80 | ALDH1A1 (0.43) | MAPTALDH1A1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL25925420 | 0.80 | MAPT (0.43) | MAPTALDH1A1HPGDCASP3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024188906-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2024-09-19 | — | — | WO | disclosed |
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2022159454-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BRDT, BRD3, BRD2 | MAPT 2774/4885ALDH1A1 3781/4885HPGD 1375/4885 |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | MAPT 3736/4885ALDH1A1 3755/4885HPGD 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.